Issue

Vol. 63 No. 12: Issue 12

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Astemizole inhibits cell proliferation in human prostate tumorigenic cells expressing ether í -go-go-1 potassium channels

https://doi.org/10.14715/10.14715/cmb/2017.63.12.4
Gloria Bernal-Ramos
Department of Genetics and Molecular Biology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Elisabeth Hernández-Gallegos
Department of Pharmacology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Eunice Vera
Department of Pharmacology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Marí­a de Guadalupe Chávez-López
Department of Pharmacology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Violeta Zúñiga-Garcí­a
Department of Pharmacology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Yesennia Sánchez-Pérez
Instituto Nacional de Cancerologí­a, Subdirección de Investigación Básica, San Fernando 22, Tlalpan, 14080, Mexico City 14080, Mexico
Efraí­n Garrido
Department of Genetics and Molecular Biology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Javier Camacho
Department of Pharmacology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico

Corresponding Author(s) : Javier Camacho

fcamacho@cinvestav.mx

Cellular and Molecular Biology, Vol. 63 No. 12: Issue 12

Abstract

Prostate cancer (PC) is the main cause of cancer mortality in men worldwide. Therefore, novel treatments for PC are needed. Ether í -go-go-1 (Eag1) potassium channels display oncogenic properties, and have been suggested as early tumor markers and therapeutic targets for different cancers. These channels are overexpressed in many human tumors including PC. Astemizole targets several molecules involved in cancer including Eag1 channels, histamine receptors and ABC transporters. Here we studied Eag1 mRNA expression and protein levels in the non-tumorigenic and non-invasive human prostate RWPE-1 cell line, and in the tumorigenic and highly invasive human prostate WPE1-NB26 cell lines. The effect of astemizole on cell proliferation and apoptosis was also studied. The human prostate cell lines RWPE-1 and WPE1-NB26 were cultured following the provider´s instructions. Eag1 mRNA expression and protein levels were studied by real time RT-PCR and immunocytochemistry, respectively. Cell proliferation and apoptosis were studied by a fluorescence AlamarBlue®  assay and flow cytometry, respectively. No difference in Eag1 mRNA expression was observed between the cell lines. However, high Eag1 protein levels were observed in the invasive WPE1-NB26 cells, in contrast to the weak protein expression in RWPE-1 cells. Accordingly, astemizole decreased cell proliferation at nanomolar concentrations only in the invasive WPE1-NB26 cells.  Our results suggest that astemizole may have clinical relevance for prostate cancer treatment in patients with high Eag1 protein levels.

Keywords

Astemizole Prostate cancer Ion channels Eag1 Anti-histamine.
Bernal-Ramos, G., Hernández-Gallegos, E., Vera, E., Chávez-López, M. de G., Zúñiga-Garcí­a, V., Sánchez-Pérez, Y., Garrido, E., & Camacho, J. (2017). Astemizole inhibits cell proliferation in human prostate tumorigenic cells expressing ether í -go-go-1 potassium channels. Cellular and Molecular Biology, 63(12), 11–13. https://doi.org/10.14715/10.14715/cmb/2017.63.12.4
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136(5):E359-86.
  2. Pardo LA, Stuhmer W. The roles of K(+) channels in cancer. Nature reviews Cancer. 2014;14(1):39-48.
  3. Wang X, Chen Y, Zhang Y, Guo S, Mo L, An H. Eag1 Voltage-Dependent Potassium Channels: Structure, Electrophysiological Characteristics, and Function in Cancer. 2017.
  4. Avila E, Garcia-Becerra R, Rodriguez-Rasgado JA, Diaz L, Ordaz-Rosado D, Zugel U, et al. Calcitriol down-regulates human ether a go-go 1 potassium channel expression in cervical cancer cells. Anticancer research. 2010;30(7):2667-72.
  5. Hartung F, Stuhmer W, Pardo LA. Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody. Molecular cancer. 2011;10:109.
  6. Zheng YQ, Li ZJ, Gao X, Zhang XB, Li FJ, Shi YJ, et al. [Expression of Eag1 K(+) channel in prostate cancer and its significance]. Zhonghua nan ke xue = National journal of andrology. 2013;19(3):205-9.
  7. Ouadid-Ahidouch H, Ahidouch A, Pardo LA. Kv10.1 K(+) channel: from physiology to cancer. Pflugers Archiv : European journal of physiology. 2016;468(5):751-62.
  8. Garcia-Quiroz J, Camacho J. Astemizole: an old anti-histamine as a new promising anti-cancer drug. Anticancer Agents Med Chem. 2011;11(3):307-14.
  9. Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, Bice G, et al. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. The Prostate. 2001;47(1):1-13.
  10. Diaz L, Ceja-Ochoa I, Restrepo-Angulo I, Larrea F, Avila-Chavez E, Garcia-Becerra R, et al. Estrogens and human papilloma virus oncogenes regulate human ether-a-go-go-1 potassium channel expression. Cancer research. 2009;69(8):3300-7.
  11. de Guadalupe Chavez-Lopez M, Perez-Carreon JI, Zuniga-Garcia V, Diaz-Chavez J, Herrera LA, Caro-Sanchez CH, et al. Astemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCC. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015;36(8):6149-58.
  12. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome biology. 2003;4(9):117.
  13. Camacho J, Sanchez A, Stuhmer W, Pardo LA. Cytoskeletal interactions determine the electrophysiological properties of human EAG potassium channels. Pflugers Archiv : European journal of physiology. 2000;441(2-3):167-74.
  14. Ramirez A, Hinojosa LM, Gonzales J, Montante-Montes D, Martinez-Benitez B, Aguilar-Guadarrama R, et al. KCNH1 potassium channels are expressed in cervical cytologies from pregnant patients and are regulated by progesterone. Reproduction (Cambridge, England). 2013;146(6):615-23.
  15. Urrego D, Movsisyan N, Ufartes R, Pardo LA. Periodic expression of Kv10.1 driven by pRb/E2F1 contributes to G2/M progression of cancer and non-transformed cells. Cell cycle (Georgetown, Tex). 2016;15(6):799-811.
Read More

Author Biographies

Gloria Bernal-Ramos, Department of Genetics and Molecular Biology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Ph.D. student
Elisabeth Hernández-Gallegos, Department of Pharmacology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Research assistant.
Eunice Vera, Department of Pharmacology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Research assistant.
Marí­a de Guadalupe Chávez-López, Department of Pharmacology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Post-doctoral fellow.
Violeta Zúñiga-Garcí­a, Department of Pharmacology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Post-doctoral fellow.
Yesennia Sánchez-Pérez, Instituto Nacional de Cancerologí­a, Subdirección de Investigación Básica, San Fernando 22, Tlalpan, 14080, Mexico City 14080, Mexico
Researcher.
Efraí­n Garrido, Department of Genetics and Molecular Biology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Researcher.
Javier Camacho, Department of Pharmacology, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City 07360, Mexico
Department of Pharmacology. Researcher.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 954 Download : 408

Similar Articles

You may also start an advanced similarity search for this article.